# Boston Scientific (BSX) Financial Model Free Excel 3-statement financial model and company analysis for Boston Scientific. - Canonical: https://finamodel.com/companies/boston-scientific - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/BSX.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool for Boston Scientific Corporation (BSX) to assess how the rapid adoption of high-growth product launches (such as the Farapulse Pulsed Field Ablation System and WATCHMAN) and recent strategic acquisitions will impact long-term revenue growth and operating margin expansion. ## Company Overview Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company operates a high-innovation, direct-sales business model that relies heavily on continuous research and development alongside strategic acquisitions to maintain category leadership. The business is organised into two primary reportable segments: Cardiovascular (approximately 55-60% of revenue) and MedSurg (approximately 40-45% of revenue). Geographically, the United States is the largest market contributing roughly 60% of sales, followed by Europe, Middle East and Africa (EMEA) at 20%, Asia-Pacific (APAC) at 15%, and Latin America and Canada (LACA) at 5%. Boston Scientific holds a top-tier competitive position in the medtech industry, competing directly with giants such as Medtronic, Abbott Laboratories, and Johnson & Johnson. Recent major events include the highly successful 2024/2025 rollout of the Farapulse system and a string of acquisitions including Axonics, Silk Road Medical, Relievant Medsystems, and Apollo Endosurgery. ## Revenue Deep Dive ### Cardiovascular - **Segment name**: Cardiovascular (combines historical Cardiology and Peripheral Interventions) - **Sub-segments**: Interventional Cardiology Therapies, WATCHMAN, Cardiac Rhythm Management (CRM), Electrophysiology, and Peripheral Interventions. - **Revenue driver formula**: Procedure Volume x Average Selling Price (ASP) per device. - **Historical growth rate**: 15-18% reported CAGR recently, heavily skewed by hyper-growth in Electrophysiology (60%+ YoY) and WATCHMAN (30%+ YoY). - **Key growth levers and headwinds**: Levers include the global shift towards pulsed field ablation (Farapulse) and left atrial appendage closure. Headwinds include hospital staffing shortages and pricing pressure from group purchasing organisations. - **Pricing dynamics**: Contractual with hospital networks; subject to reimbursement rate changes by Medicare and private insurers. - **Revenue recognition notes**: Recognised at the point in time when control transfers to the customer (typically upon delivery or hospital consumption from consigned inventory). - **Seasonality**: Q4 is historically the strongest quarter due to hospital capital budget flushes and patients scheduling elective procedures after meeting annual health insurance deductibles. ### MedSurg - **Segment name**: MedSurg - **Sub-segments**: Endoscopy, Urology, and Neuromodulation. - **Revenue driver formula**: Procedure Volume x Average Selling Price (ASP) per device. - **Historical growth rate**: 10-12% reported CAGR. - **Key growth levers and headwinds**: Levers include the integration of the Axonics acquisition (sacral neuromodulation) and single-use imaging devices. Headwinds include delayed elective procedures and supply chain constraints. - **Pricing dynamics**: Similar to Cardiovascular, driven by hospital contracts and reimbursement codes. - **Revenue recognition notes**: Point-in-time recognition upon delivery or consumption. - **Seasonality**: Mirrors the broader business, with Q4 being the strongest period. ## Cost Structure ### Variable Costs / COGS - COGS includes raw materials, direct labour, manufacturing overhead, freight, and inventory charges. - **Gross margin range**: 68.0% to 70.0% over the last 5 years (69.0% in 2025). - **Key input costs**: Electronic components, precious metals, plastics, and sterilisation services. - COGS scales linearly with volume, though gross margin percentage improves slightly with a mix-shift towards higher-margin innovative devices like WATCHMAN. ### Operating Expenses - **R&D**: Typically runs at 9.5% to 10.5% of revenue. It covers clinical trials, regulatory submissions, and product engineering. Most R&D is expensed as incurred. - **SG&A**: Typically 33.0% to 35.0% of revenue. This is heavily headcount-driven, supporting a massive global direct sales force and physician training programmes. - **Depreciation & Amortisation**: High (roughly 7-9% of revenue), with the majority being amortisation of intangible assets acquired through serial M&A. - **Stock-Based Compensation**: Approximately 1.5% to 2.0% of revenue. - **Restructuring / one-time charges**: Frequent due to continuous M&A integration and global supply chain optimisation programmes. ### Margin Profile - **Gross margin**: 68.0% to 70.0%. - **Adjusted Operating margin**: Expanding from 27.0% in 2024 to 28.0% in 2025. - **GAAP Operating margin**: Significantly lower (12.0% to 17.0%) due to heavy acquisition-related amortisation and litigation charges. - **Margin trend**: Expanding due to operating leverage on SG&A and a favourable product mix shift towards high-growth, high-margin electrophysiology products. ## Balance Sheet Structure - **Total assets**: Approximately $35 billion to $40 billion. - **Key asset categories**: Goodwill and Intangible Assets dominate the balance sheet, representing over 50% of total assets due to the company's aggressive acquisition strategy. - **Working capital profile**: - **Days Sales Outstanding (DSO)**: 55 to 65 days. - **Days Inventory Outstanding (DIO)**: 110 to 130 days (high inventory is required to support consigned inventory models in hospitals). - **Days Payable Outstanding (DPO)**: 40 to 50 days. - **Net working capital**: Positive, representing a use of cash as the business grows. - **PP&E**: Consists of global manufacturing facilities (e.g., Costa Rica, Ireland, Malaysia) and distribution centres. Useful lives range from 3 to 40 years. - **Right-of-use assets**: Material but manageable, representing standard facility and equipment operating leases. ## Capital Expenditure & Investment - **Capex as % of revenue**: 4.0% to 5.0%. - **Maintenance vs. growth**: Roughly 40% maintenance and 60% growth (expanding manufacturing capacity for new product lines). - **Capitalised software**: Minimal relative to total capex; mostly internal-use ERP systems. - **M&A pattern**: Serial acquirer. The company executes both bolt-on acquisitions and transformational deals (e.g., Axonics, Silk Road Medical), spending $1 billion to $3 billion+ annually. - **Typical acquisition multiple**: Often pays high revenue multiples (5x to 10x forward sales) for pre-revenue or high-growth clinical-stage medtech assets. ## Debt & Capital Structure - **Total debt**: Approximately $10 billion to $12 billion. - **Debt/EBITDA ratio**: Targets a gross leverage ratio of 2.0x to 2.5x. - **Credit rating**: Investment grade (typically BBB+ / Baa1). - **Key debt instruments**: Euro-denominated and US Dollar senior notes, backed by a $2.75 billion revolving credit facility. - **Maturity profile**: Well-laddered with average maturities exceeding 5 years. - **Interest rate profile**: Predominantly fixed-rate senior notes. - **Share repurchase programme**: Active $1.0 billion authorisation, though management frequently pauses buybacks to fund large acquisitions. - **Dividend policy**: The company does not currently pay a regular cash dividend, preferring to deploy capital into M&A and internal R&D. ## Cash Flow Characteristics - **Operating cash flow conversion**: Strong, typically exceeding 100% of GAAP Net Income due to massive non-cash amortisation add-backs. - **Free cash flow margin**: 15.0% to 18.0% ($3.66 billion FCF on $20.0 billion revenue in 2025). - **Major non-cash items**: Amortisation of intangibles, stock-based compensation, and deferred income taxes. - **Working capital cash flow impact**: Inventory builds are a consistent use of cash to support double-digit revenue growth. - **Cash tax rate**: Often lower than the statutory rate due to R&D tax credits and manufacturing in tax-advantaged jurisdictions like Puerto Rico and Costa Rica. ## Sheet Structure 1. **Assumptions**: Hardcoded inputs for macroeconomic drivers, segment growth rates, margin profiles, and working capital days. 2. **Revenue Build**: Detailed build forecasting MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular (Interventional Cardiology, WATCHMAN, CRM, Electrophysiology, Peripheral Interventions) based on volume and pricing assumptions. 3. **Income Statement**: Standard P&L from Revenue down to Net Income, with a clear bridge between GAAP Operating Income and Adjusted Operating Income. 4. **Balance Sheet**: Assets, Liabilities, and Shareholders' Equity, mirroring the 10-K presentation. 5. **Cash Flow Statement**: Operating, Investing, and Financing cash flows, calculating Free Cash Flow. 6. **Working Capital Schedule**: Projections for Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO. 7. **Depreciation & Amortisation Schedule**: Waterfall schedules for PP&E capex and Intangible asset amortisation. 8. **Debt Schedule**: Tracking senior notes, revolving credit facility drawdowns, interest expense, and mandatory repayments. 9. **DCF Valuation**: Unlevered free cash flow calculation, WACC derivation, terminal value, and implied share price. ## Key Financial Relationships 1. `Cardiovascular Revenue = Interventional Cardiology + WATCHMAN + Cardiac Rhythm Management + Electrophysiology + Peripheral Interventions` 2. `MedSurg Revenue = Endoscopy + Urology + Neuromodulation` 3. `Total Net Sales = Cardiovascular Revenue + MedSurg Revenue` 4. `Gross Profit = Total Net Sales - Cost of Products Sold` 5. `Adjusted Operating Income = Gross Profit - SG&A - R&D` (Excludes amortisation and acquisition-related charges) 6. `GAAP Operating Income = Adjusted Operating Income - Amortisation of Intangible Assets - Contingent Consideration Adjustments - Restructuring Charges` 7. `Accounts Receivable = (Total Net Sales / 365) * DSO` 8. `Inventory = (Cost of Products Sold / 365) * DIO` 9. `Accounts Payable = (Cost of Products Sold / 365) * DPO` 10. `Free Cash Flow = Net Cash Provided by Operating Activities - Purchases of Property, Plant, and Equipment` 11. `Interest Expense = Average Total Debt Balance * Weighted Average Interest Rate` 12. `Adjusted Net Income = GAAP Net Income + After-Tax Impact of Amortisation and Special Charges` ## Cross-Sheet Dependencies - The **Assumptions** sheet dictates the growth and margin profiles used in the **Revenue Build** and **Income Statement**. - The **Revenue Build** feeds the top line of the **Income Statement**. - **Income Statement** outputs (Net Income, D&A) feed the top of the **Cash Flow Statement**. - The **Working Capital Schedule** calculates the change in NWC, which feeds the **Cash Flow Statement**. - The **Debt Schedule** calculates interest expense, which feeds the **Income Statement**, creating a potential circularity if debt paydown is linked to cash sweeps. - The **Cash Flow Statement** calculates the net change in cash, which feeds the Cash line on the **Balance Sheet** to ensure it balances. ## Sign Convention - **Revenue and Assets**: Entered and displayed as positive numbers. - **Expenses (COGS, SG&A, R&D)**: Entered as positive numbers in assumptions, but subtracted in formulas to calculate margins and profit. - **Liabilities and Equity**: Entered and displayed as positive numbers. - **Cash Flow Statement**: Cash inflows are positive; cash outflows (e.g., Capex, debt repayment, dividends) are negative. ## Things Most Likely to Go Wrong - **Conflating GAAP and Adjusted Margins**: Boston Scientific's GAAP operating margin is heavily depressed by intangible amortisation. The model must clearly separate Adjusted Operating Margin (which management guides to) from GAAP metrics. - **Underestimating Electrophysiology Growth**: The Farapulse launch has caused the Electrophysiology sub-segment to grow at 60%+ YoY. Applying a generic segment growth rate will severely underestimate Cardiovascular revenue. - **Inventory Miscalculations**: Medical device companies require massive consigned inventory. DIO runs very high (110+ days). Assuming standard manufacturing DIO will artificially inflate operating cash flow. - **Acquisition Stub Periods**: The company frequently closes mid-year acquisitions (e.g., Axonics). The model must account for partial-year revenue contributions in the historical and first projected years. - **Foreign Exchange Drag**: The company reports both "operational" (constant currency) and "reported" growth. The model should forecast on a reported basis but acknowledge that a strong USD will compress international revenue yields. - **Contingent Consideration Liabilities**: M&A deals often include earn-outs. Changes in the fair value of these liabilities hit the GAAP P&L and can cause wild swings in quarterly net income. - **Stock-Based Compensation**: Excluding SBC from adjusted metrics flatters margins. The model must capture SBC as a real dilution cost in the valuation. - **Tax Rate Volatility**: The GAAP effective tax rate fluctuates wildly due to discrete tax items and IP realignments. The model should use the management-guided adjusted tax rate for normalised forecasting. ## Validation Checks - "Gross margin should remain in the 68.0% to 70.0% range; flag if it falls outside this band." - "Adjusted Operating Margin should show steady expansion towards 28.0% - 29.0% based on management's long-term guidance." - "Free Cash Flow conversion (FCF / Adjusted Net Income) should be > 80%." - "Days Inventory Outstanding (DIO) must remain above 110 days to reflect the consigned inventory model." - "Total Assets must equal Total Liabilities plus Shareholders' Equity in every forecast period." - "Capex as a percentage of revenue should remain between 4.0% and 5.0%." - "Gross Debt to EBITDA should not exceed 3.0x without triggering a warning flag for potential credit rating downgrade." - "R&D expense should not drop below 9.0% of revenue, as this would signal underinvestment in the product pipeline." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Cardiovascular Revenue Growth | 15.0 | % | Blended rate driven by hyper-growth in Electrophysiology and WATCHMAN, offset by mature CRM. | | MedSurg Revenue Growth | 10.0 | % | Steady growth supported by Urology acquisitions and Endoscopy volume recovery. | | Gross Margin | 69.0 | % | Based on 2025 actuals and product mix shift towards higher-margin devices. | | R&D as % of Revenue | 10.0 | % | Historical average required to maintain category leadership and clinical trials. | | SG&A as % of Revenue | 34.0 | % | Reflects the high cost of maintaining a global direct sales force. | | Adjusted Effective Tax Rate | 13.0 | % | Management guidance reflecting manufacturing in tax-advantaged jurisdictions. | | Days Sales Outstanding (DSO) | 60 | Days | Historical average for hospital and clinic receivables. | | Days Inventory Outstanding (DIO) | 120 | Days | High requirement for global supply chain and consigned hospital inventory. | | Days Payable Outstanding (DPO) | 45 | Days | Historical average for supplier payment terms. | | Capex as % of Revenue | 4.5 | % | Blended rate of maintenance and capacity expansion for new product lines. | | Weighted Average Interest Rate | 4.5 | % | Based on the current yield of outstanding senior notes and recent Euro debt issuance. | | Share Count (Diluted) | 1,490 | Millions | Based on 2025 year-end diluted shares outstanding. | | WACC | 8.0 | % | Standard discount rate for a large-cap, diversified medtech company. | | Terminal Growth Rate | 2.5 | % | Aligns with long-term global healthcare spending and GDP growth. | ## Data Sources & Benchmarks - **Filings**: SEC EDGAR database for BSX 10-K, 10-Q, and 8-K filings. - **Investor Relations**: Boston Scientific Investor Relations website for earnings presentations, non-GAAP reconciliations, and Investor Day transcripts. - **Peers for Benchmarking**: Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Edwards Lifesciences (EW), and Johnson & Johnson (JNJ) MedTech segment. - **Industry Data**: IQVIA for medical device procedure volumes, CMS.gov for Medicare reimbursement rate changes. - **Consensus Estimates**: FactSet or Bloomberg for forward-looking street estimates on revenue and adjusted EPS. ## Sources - Boston Scientific Corporation Form 10-K for the fiscal years ended December 31, 2024, and December 31, 2025. - Boston Scientific Q4 2024 and Q4 2025 Earnings Press Releases and Financial & Operational Highlights presentations. - Boston Scientific 2024 and 2025 Annual Reports to Stockholders. - SEC EDGAR Database (https://www.sec.gov/edgar). - Boston Scientific Investor Relations (https://investors.bostonscientific.com). --- ## Frequently asked questions ### What kind of company is Boston Scientific and what medical devices do they produce? Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company operates a high-innovation, direct-sales business model, relying heavily on continuous research and development alongside strategic acquisitions. ### What are the primary drivers of Boston Scientific's revenue growth? Boston Scientific's revenue growth is primarily driven by the rapid adoption of high-growth product launches, such as the Farapulse Pulsed Field Ablation System and WATCHMAN. Recent strategic acquisitions also play a significant role in impacting long-term revenue expansion. ### What is the assumed long-term revenue growth rate in the Boston Scientific financial model? The financial model for Boston Scientific assumes a long-term revenue growth rate of approximately 7.3%. This forecast considers the impact of new product introductions and strategic acquisitions on the company's top line. ### How does Boston Scientific's aggressive acquisition strategy impact its balance sheet and valuation model inputs? Boston Scientific's aggressive acquisition strategy leads to Goodwill and Intangible Assets dominating its balance sheet, representing over 50% of total assets. This significant proportion of intangible assets is a crucial input for equity valuation and scenario planning tools. ### Can I download an Excel financial model for Boston Scientific (BSX)? Yes, a comprehensive Excel financial model for Boston Scientific (BSX) is available for download. This model serves as an equity valuation and scenario planning tool, allowing users to assess various financial impacts. ### What is Boston Scientific's capital expenditure strategy? Boston Scientific typically allocates 4.0% to 5.0% of its revenue to capital expenditures. Roughly 60% of this capex is directed towards growth initiatives, primarily expanding manufacturing capacity for new product lines. [Interactive forecast calculator](https://finamodel.com/companies/boston-scientific/forecast)